Novogaia develops new medicines by rapidly characterizing fungal chemical space and mapping it to de-risked biological targets. The company utilizes machine learning systems to decode drug-like molecular structures from natural samples with high accuracy. This process focuses on identifying novel therapeutic candidates for areas with unmet medical needs.
Funding
Funding not disclosed
Founders
Product
Problem
The vast chemical diversity of fungi remains largely unexplored, with less than 1% of fungal chemistries currently understood. This limited knowledge hinders the discovery of novel natural products with potential applications in pharmaceuticals, agriculture, and other industries.
Solution
Novogaia employs machine learning and metabologenomics to decode the biosynthetic pathways of fungi and accelerate the discovery of novel natural products. By mining fungal genomes and using computational metabolomics, the company predicts the structures and properties of small molecules produced by biosynthetic gene clusters (BGCs). Multi-omics analysis and machine learning are then used to predict the biological activities of these molecules, creating a comprehensive map of fungal chemistry. This approach enables the identification of previously untapped compounds with the potential to revolutionize various industries.
Target Audience
Novogaia's primary customers are companies in the pharmaceuticals and agrochemicals industries seeking to discover and develop novel natural products.
Features
- Target-directed mining of fungal genomes to detect biosynthetic gene clusters (BGCs)
- Computational metabolomic tools to predict small molecules produced by BGCs
- Machine learning and multi-omics analysis to predict the structures and activities of molecules
- Creation of a comprehensive map of fungal chemistry